Back to search
Cytomegaloviral Infection
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Cytomegaloviral Infection trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Cytomegaloviral Infection trials you may qualify forThis is a Phase 1 single-arm open-label study of letermovir in neonates with symptomatic congenital Cytomegalovirus (CMV) disease. There will be two groups enro…
The purpose of this study is to evaluate the efficacy and safety of a personalized strategy for discontinuing Letermovir (a drug used to prevent Cytomegalovirus…
This phase III single arm trial determines whether taking prophylactic letermovir will reduce the likelihood of infection with cytomegalovirus (CMV) in children…
This phase I trial tests the feasibility and safety of genetically modified cytotoxic T-lymphocytes in controlling infections caused by adenovirus (ADV), BK vir…
This is a phase II trial with an initial safety lead-in evaluating the efficacy, safety, neurocognitive, and quality-of-life outcomes of anti-cytomegalovirus (C…
This observational retrospective analysis will provide useful information for clinicians and payers, and local guidelines committee members, to improve the unde…
The purpose of this study is to find out whether letermovir can help prevent cytomegalovirus (CMV) infection in kidney transplant recipients who are CMV seropos…
Cytomegalovirus (CMV) remains a significant cause of morbidity and mortality following organ transplantation. Cell-mediated immunity plays a crucial role in co…